Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 128

1.

Belinostat and panobinostat (HDACI): in vitro and in vivo studies in thyroid cancer.

Chan D, Zheng Y, Tyner JW, Chng WJ, Chien WW, Gery S, Leong G, Braunstein GD, Koeffler HP.

J Cancer Res Clin Oncol. 2013 Sep;139(9):1507-14. doi: 10.1007/s00432-013-1465-6. Epub 2013 Jul 4.

2.

Growth inhibition of pancreatic cancer cells by histone deacetylase inhibitor belinostat through suppression of multiple pathways including HIF, NFkB, and mTOR signaling in vitro and in vivo.

Chien W, Lee DH, Zheng Y, Wuensche P, Alvarez R, Wen DL, Aribi AM, Thean SM, Doan NB, Said JW, Koeffler HP.

Mol Carcinog. 2014 Sep;53(9):722-35. doi: 10.1002/mc.22024. Epub 2013 Mar 8.

3.

Experimental in vivo and in vitro treatment with a new histone deacetylase inhibitor belinostat inhibits the growth of pancreatic cancer.

Dovzhanskiy DI, Arnold SM, Hackert T, Oehme I, Witt O, Felix K, Giese N, Werner J.

BMC Cancer. 2012 Jun 8;12:226. doi: 10.1186/1471-2407-12-226.

4.

Panobinostat synergistically enhances the cytotoxic effects of cisplatin, doxorubicin or etoposide on high-risk neuroblastoma cells.

Wang G, Edwards H, Caldwell JT, Buck SA, Qing WY, Taub JW, Ge Y, Wang Z.

PLoS One. 2013 Sep 30;8(9):e76662. doi: 10.1371/journal.pone.0076662. eCollection 2013.

5.

Cytotoxic activity of the histone deacetylase inhibitor panobinostat (LBH589) in anaplastic thyroid cancer in vitro and in vivo.

Catalano MG, Pugliese M, Gargantini E, Grange C, Bussolati B, Asioli S, Bosco O, Poli R, Compagnone A, Bandino A, Mainini F, Fortunati N, Boccuzzi G.

Int J Cancer. 2012 Feb 1;130(3):694-704. doi: 10.1002/ijc.26057. Epub 2011 May 5.

6.

Utility of a histone deacetylase inhibitor (PXD101) for thyroid cancer treatment.

Lin SF, Lin JD, Chou TC, Huang YY, Wong RJ.

PLoS One. 2013 Oct 14;8(10):e77684. doi: 10.1371/journal.pone.0077684. eCollection 2013.

7.

Targeting triple-negative breast cancer cells with the histone deacetylase inhibitor panobinostat.

Tate CR, Rhodes LV, Segar HC, Driver JL, Pounder FN, Burow ME, Collins-Burow BM.

Breast Cancer Res. 2012 May 21;14(3):R79.

8.

Sustained inhibition of deacetylases is required for the antitumor activity of the histone deactylase inhibitors panobinostat and vorinostat in models of colorectal cancer.

Wilson PM, Labonte MJ, Martin SC, Kuwahara ST, El-Khoueiry A, Lenz HJ, Ladner RD.

Invest New Drugs. 2013 Aug;31(4):845-57. doi: 10.1007/s10637-012-9914-7. Epub 2013 Jan 9.

PMID:
23299388
9.

Synergistic antitumor interactions between MK-1775 and panobinostat in preclinical models of pancreatic cancer.

Wang G, Niu X, Zhang W, Caldwell JT, Edwards H, Chen W, Taub JW, Zhao L, Ge Y.

Cancer Lett. 2015 Jan 28;356(2 Pt B):656-68. doi: 10.1016/j.canlet.2014.10.015. Epub 2014 Oct 18.

10.

Differential effects of PXD101 (belinostat) on androgen-dependent and androgen-independent prostate cancer models.

Gravina GL, Marampon F, Giusti I, Carosa E, Di Sante S, Ricevuto E, Dolo V, Tombolini V, Jannini EA, Festuccia C.

Int J Oncol. 2012 Mar;40(3):711-20. doi: 10.3892/ijo.2011.1270. Epub 2011 Nov 23.

PMID:
22134754
11.

The HDACi Panobinostat Shows Growth Inhibition Both In Vitro and in a Bioluminescent Orthotopic Surgical Xenograft Model of Ovarian Cancer.

Helland Ø, Popa M, Bischof K, Gjertsen BT, McCormack E, Bjørge L.

PLoS One. 2016 Jun 28;11(6):e0158208. doi: 10.1371/journal.pone.0158208. eCollection 2016.

12.

The dual EGFR/HER2 inhibitor lapatinib synergistically enhances the antitumor activity of the histone deacetylase inhibitor panobinostat in colorectal cancer models.

LaBonte MJ, Wilson PM, Fazzone W, Russell J, Louie SG, El-Khoueiry A, Lenz HJ, Ladner RD.

Cancer Res. 2011 May 15;71(10):3635-48. doi: 10.1158/0008-5472.CAN-10-2430. Epub 2011 Apr 4.

13.

Targeting histone deacetylases (HDACs) and Wee1 for treating high-risk neuroblastoma.

Hanmod SS, Wang G, Edwards H, Buck SA, Ge Y, Taub JW, Wang Z.

Pediatr Blood Cancer. 2015 Jan;62(1):52-9. doi: 10.1002/pbc.25232. Epub 2014 Oct 12.

PMID:
25308916
14.

Romidepsin and belinostat synergize the antineoplastic effect of bortezomib in mantle cell lymphoma.

Paoluzzi L, Scotto L, Marchi E, Zain J, Seshan VE, O'Connor OA.

Clin Cancer Res. 2010 Jan 15;16(2):554-65. doi: 10.1158/1078-0432.CCR-09-1937. Epub 2010 Jan 12.

15.

The HDAC inhibitor, MPT0E028, enhances erlotinib-induced cell death in EGFR-TKI-resistant NSCLC cells.

Chen MC, Chen CH, Wang JC, Tsai AC, Liou JP, Pan SL, Teng CM.

Cell Death Dis. 2013 Sep 19;4:e810. doi: 10.1038/cddis.2013.330.

16.

Gene expression-signature of belinostat in cell lines is specific for histone deacetylase inhibitor treatment, with a corresponding signature in xenografts.

Monks A, Hose CD, Pezzoli P, Kondapaka S, Vansant G, Petersen KD, Sehested M, Monforte J, Shoemaker RH.

Anticancer Drugs. 2009 Sep;20(8):682-92. doi: 10.1097/CAD.0b013e32832e14e1.

PMID:
19606018
17.

The histone deacetylase inhibitor belinostat (PXD101) suppresses bladder cancer cell growth in vitro and in vivo.

Buckley MT, Yoon J, Yee H, Chiriboga L, Liebes L, Ara G, Qian X, Bajorin DF, Sun TT, Wu XR, Osman I.

J Transl Med. 2007 Oct 12;5:49.

18.

The histone deacetylase inhibitor PXD101 increases the efficacy of irinotecan in in vitro and in vivo colon cancer models.

Na YS, Jung KA, Kim SM, Hong YS, Ryu MH, Jang SJ, Moon DH, Cho DH, Kim JC, Lee JS, Kim TW.

Cancer Chemother Pharmacol. 2011 Aug;68(2):389-98. doi: 10.1007/s00280-010-1495-6. Epub 2010 Nov 3.

PMID:
21046105
19.

Resveratrol sensitizes acute myelogenous leukemia cells to histone deacetylase inhibitors through reactive oxygen species-mediated activation of the extrinsic apoptotic pathway.

Yaseen A, Chen S, Hock S, Rosato R, Dent P, Dai Y, Grant S.

Mol Pharmacol. 2012 Dec;82(6):1030-41. doi: 10.1124/mol.112.079624. Epub 2012 Aug 24.

20.

Belinostat and vincristine demonstrate mutually synergistic cytotoxicity associated with mitotic arrest and inhibition of polyploidy in a preclinical model of aggressive diffuse large B cell lymphoma.

Havas AP, Rodrigues KB, Bhakta A, Demirjian JA, Hahn S, Tran J, Scavello M, Tula-Sanchez AA, Zeng Y, Schmelz M, Smith CL.

Cancer Biol Ther. 2016 Dec;17(12):1240-1252. doi: 10.1080/15384047.2016.1250046. Epub 2016 Oct 28.

Supplemental Content

Support Center